-
Nicotine Signaling and CKD Progression: Evidence
2026-09-01
The reference review integrates clinical and experimental evidence that nicotine contributes to chronic kidney disease progression through non-neuronal nicotinic acetylcholine receptors, oxidative stress, hemodynamic changes, and pro-fibrotic signaling. Its main practical contribution is a mechanistic framework for separating nicotine-specific effects from the broader toxicology of cigarette smoke and for designing translational kidney studies.
-
Br-DAPI: From DNA Signal to Cardiac Insight
2026-09-01
A translational perspective on how Br-DAPI can strengthen DNA quantification and nuclear imaging in diabetic cardiomyopathy research without confusing structural readouts with direct measures of viability, lipotoxicity, or ER stress.
-
CHIR 99021 trihydrochloride in Organoid Workflows
2026-08-31
Learn how to use CHIR 99021 trihydrochloride as a tunable GSK-3 inhibitor for organoid expansion, lineage control, and metabolic disease modeling. This workflow separates evidence from practical optimization so researchers can distinguish enhanced stemness from terminal differentiation.
-
Depleting TAMs to Decode Immunotherapy Resistance
2026-08-31
Macrophage CCL7 is emerging as a mechanistic driver of colorectal cancer immunotherapy resistance. This thought-leadership guide explains how Clodronate Liposomes can function as a causal perturbation tool alongside genetic and molecular approaches, while highlighting the controls, validation steps, and translational limits required for rigorous interpretation.
-
Chuanxiong Cortex–Pith Mechanisms in Coronary Heart Disease
2026-08-30
The reference study distinguishes the volatile chemistry and predicted pharmacology of Ligusticum chuanxiong cortex and pith using SPME-GC×GC-MS, network pharmacology, and molecular docking. Its results position Fenipentol among the principal cortex-associated candidates while showing that plant-tissue selection can substantially alter the molecular mechanisms inferred for coronary heart disease research.
-
Paeoniflorin Targets Tmem176b+ Macrophages in Liver I/R
2026-08-29
A 2025 study used single-cell RNA sequencing and functional perturbation to identify Tmem176b+ macrophages as a key cellular target of paeoniflorin in hepatic ischemia-reperfusion injury. The findings connect macrophage-state conversion with THBS1-CD47 and SPP1-CD44 signaling, providing a more precise framework for studying immune regulation during liver injury.
-
AP-2α, MGMT, and TMZ Resistance in Recurrent GBM
2026-08-28
The reference study identifies AP-2α as an upstream transcriptional suppressor of MGMT in recurrent glioblastoma, linking loss of this factor to temozolomide resistance and weaker DNA damage. Its cell, promoter-regulation, and intracranial-model experiments suggest that restoring AP-2α activity, including through retinoic acid signaling, may improve TMZ response, although clinical translation remains unproven.
-
Bafilomycin A1 in Lysosome–Centrosome Assays
2026-08-28
Bafilomycin A1 is a reversible V-ATPase inhibitor that can separate lysosomal acidification effects from centrosome-proteostasis phenotypes. This article translates recent Kif9–centriolar satellite findings into a spatially informed assay strategy while defining the limits of pharmacological interpretation.
-
Annexin V-FITC/PI Apoptosis Assay Kit Workflow
2026-08-27
Use stage-resolved fluorescence to distinguish viable, early apoptotic, and membrane-compromised cells in oxidative-stress and treatment-response experiments. This workflow translates the ARPE-19 caffeine study into practical assay design, gating, controls, and troubleshooting guidance.
-
UBC9, PINK1 SUMOylation, and Mitophagy in PD
2026-08-27
The reference study identifies UBC9-mediated SUMOylation of PINK1 as a mechanistic link between mitochondrial quality control, oxidative stress, and Parkinson’s disease-related neurotoxicity. Its combined cellular, biochemical, and mouse-model evidence supports further investigation of PINK1 modification and mitophagy, while also illustrating the controls needed for rigorous co-immunoprecipitation studies.
-
Ibrexafungerp: pH-Ready Antifungal Workflows
2026-08-26
Build a practical Candida susceptibility workflow around Ibrexafungerp, also known as MK 3118, with paired neutral- and acidic-pH testing. The approach is especially useful for fluconazole-resistant isolates, vaginal-pathway research, and translational studies that connect plate-based results with resistant-infection models.
-
5X Protein Loading Buffer (Reducing) Guide
2026-08-26
5X Protein Loading Buffer (Reducing) prepares protein samples for conventional SDS-PAGE by combining SDS-mediated denaturation with disulfide-bond reduction and tracking-dye visualization. It is intended for reducing, denaturing workflows and should not be used when native conformation or non-reducing conditions must be preserved.
-
Vancomycin Hydrochloride: From MIC to Mechanism
2026-08-25
Vancomycin hydrochloride is a mechanistically defined glycopeptide antibacterial agent and a powerful reference reagent for Gram-positive bacteria inhibition. This guide explains how to move beyond endpoint MIC values by integrating target biology, exposure design, resistance readouts, and infection-model interpretation.
-
Saquinavir: Permeability and Protease Workflows
2026-08-25
Use Saquinavir as a mechanistic benchmark across HIV protease inhibition and biomimetic membrane-permeability assays. This workflow combines protease activity measurements with IAM-LC, OT-CEC, and MS to distinguish antiviral potency from transport-related behavior.
-
Nociceptor CGRP–cDC1 Signaling in Vitiligo
2026-08-24
The reference study identifies a neuroimmune circuit in which nociceptor-derived CGRP activates dermal cDC1s through a CGRP receptor axis, strengthening cDC1–CD8+ T cell interactions and melanocyte destruction. Genetic and pharmacological disruption of this pathway reduced depigmentation in mice, while a pilot topical rimegepant study supports further investigation in human vitiligo.